Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Harvard Business School
Johnson and Johnson
Colorcon
Medtronic

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

BEPREVE Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Bepreve patents expire, and when can generic versions of Bepreve launch?

Bepreve is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has forty-five patent family members in sixteen countries.

The generic ingredient in BEPREVE is bepotastine besilate. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the bepotastine besilate profile page.

Drug patent expirations by year for BEPREVE
Drug Prices for BEPREVE

See drug prices for BEPREVE

Recent Clinical Trials for BEPREVE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Southern California College of OptometryPhase 4
McCabe Vision CenterN/A
Bausch & Lomb IncorporatedPhase 4

See all BEPREVE clinical trials

Recent Litigation for BEPREVE

Identify potential future generic entrants

PTAB Litigation
PetitionerDate
Mylan Pharmaceuticals, Inc.2016-06-08
Mylan Pharmaceuticals, Inc.2016-02-25

See all BEPREVE litigation

Pharmacology for BEPREVE
Synonyms for BEPREVE
(+)-(S)-4-(4-((4-Chlorophenyl)(2-pyridyl)methoxy)piperidino)butyric acid monobenzenesulfonate
(+)-(S)-4-[4-[1-(4-Chlorophenyl)-1-(2-pyridyl)methoxy]piperidin-1-yl]butyric acid benzenesulfonate
(S)-4-(4-((4-chlorophenyl)(pyridin-2-yl)methoxy)piperidin-1-yl)butanoic acid compound with benzenesulfonic acid (1:1)
(S)-4-[4-(4-Chlorophenyl-2-pyridylmethoxy)piperidinyl]butyric Acid Benzenesulfonate
(s)-4-[4-[(4-chlorophenyl)(2-pyridyl)-methoxy]piperidino]butanoic acid monobenzenesulfonic acid salt
(s)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butanoic acid monobenzenesulfonic acid salt
1-Piperidinebutanoic acid, 4-((4-chlorophenyl)-2-pyridinylmethoxy)- (S)-, monobenzenesulfonate
1-piperidinebutanoic acid, 4-[(4-chlorophenyl)-2-pyridinylmethoxy]-, (s)-, monobenzenesulfonate
1-piperidinebutanoic acid, 4-[(s)-(4-chlorophenyl)-2-pyridinylmethoxy]-, monobenzenesulfonate
190786-44-8
4-((4-Chlorophenyl)-2-pyridinylmethoxy)- (S)-1-piperidinebutanoic acid monobenzenesulfonate
4-[(S)-(4-Chlorophenyl)-2-pyridinylmethoxy]-1-piperidinebutanoic Acid Benzenesulfonate
4-[4-[(r)-(4-chlorophenyl)-pyridin-2-yl-methoxy]-1-piperidyl]butanoic acid
4-{4-[(s)-(4-chlorophenyl)(pyridin-2-yl)methoxy]piperidin-1-yl}butanoic acid benzenesulfonate
6W18MO1QR3
786B448
ABP001064
AC-24015
AC1L4UXJ
AC1Q6WSY
AK322015
AKOS025401655
AN-5247
API0001668
AS-17863
BC214879
benzenesulfonic acid; 4-[4-[(S)-(4-chlorophenyl)-(2-pyridyl)methoxy]-1-piperidyl]butanoic acid
benzenesulfonic acid; 4-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid
benzenesulfonic acid;4-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid
Bepomax
Bepotastine (Beslilate)
Bepotastine benzenesulfonate
Bepotastine Benzenesulfonate Salt
Bepotastine besilate
Bepotastine besilate (JP17)
Bepotastine Besitate
Bepotastine Beslilat
Bepotastine besylate
Bepotastine besylate (USAN)
Bepotastine besylate [USAN]
Bepreve (TN)
Betotastine besilate
C27H31ClN2O6S
CB0259
CHEBI:31281
CHEMBL1201759
CS-0383
CTK4E0497
D01654
DTXSID80172577
FT-0655883
HY-A0015
J-012325
KS-00000FR0
LS-114358
MolPort-005-938-034
PubChem19122
s3037
SB17505
SC-47417
SCHEMBL1287638
SW220161-1
Talion
Talion (TN)
Tau 284
TAU-284
tau284
UDGHXQPQKQPSBB-BOXHHOBZSA-N
UNII-6W18MO1QR3
V2224
W-5279
Paragraph IV (Patent) Challenges for BEPREVE
Tradename Dosage Ingredient NDA Submissiondate
BEPREVE SOLUTION/DROPS;OPHTHALMIC bepotastine besilate 022288 2013-09-09

US Patents and Regulatory Information for BEPREVE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb Inc BEPREVE bepotastine besilate SOLUTION/DROPS;OPHTHALMIC 022288-001 Sep 8, 2009 AT RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Bausch And Lomb Inc BEPREVE bepotastine besilate SOLUTION/DROPS;OPHTHALMIC 022288-001 Sep 8, 2009 AT RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Bausch And Lomb Inc BEPREVE bepotastine besilate SOLUTION/DROPS;OPHTHALMIC 022288-001 Sep 8, 2009 AT RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Mallinckrodt
Johnson and Johnson
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.